Last update 02 May 2024
Astellas Pharma, Inc.

Astellas Pharma, Inc.

Public Company|
2005|
Tokyo-to, Japan
|
10,000-50,000
| TYO: 4503|

Overview

Basic Info

Introduction
Astellas Pharma Inc. is a pharmaceutical company with a global presence. The company's core products include anticancer agents, treatments for overactive bladder, and immunosuppressants for organ transplantation. Astellas' competitiveness stems from its innovative R&D and extensive network, which includes cutting-edge technology gained through collaborations with academia, bio-ventures, and pharmaceutical companies worldwide. Astellas has implemented the "Focus Area Approach" as its R&D strategy, focusing on building sustainable and expandable drug discovery by selecting the best combination of biology, modality/technology, and disease. The company has identified four prioritized research areas: Blindness & Regeneration, Mitochondria Biology, Genetic Regulation, and Immuno-Oncology, named "Primary Focus" where it strategically expands its pipeline. Collaborations with academic labs and various pharmaceutical companies, including start-ups, are a key focus for Astellas. Dedicated teams have been assigned to maximize the value of these collaborations, including Astellas Innovation Management, Business Development, and Astellas Venture Management.

Tags

Neoplasms
Other Diseases
Nervous System Diseases
Small molecule drug
AAV based gene therapy
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug84
AAV based gene therapy14
Monoclonal antibody12
Antibody drug conjugate (ADC)6
Gene therapy4

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Jun 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
6
38
Preclinical
Phase 1 Clinical
22
23
Phase 2 Clinical
Phase 3 Clinical
4
1
NDA/BLA
Approved
53
434
Other
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free